<code id='B234AED44A'></code><style id='B234AED44A'></style>
    • <acronym id='B234AED44A'></acronym>
      <center id='B234AED44A'><center id='B234AED44A'><tfoot id='B234AED44A'></tfoot></center><abbr id='B234AED44A'><dir id='B234AED44A'><tfoot id='B234AED44A'></tfoot><noframes id='B234AED44A'>

    • <optgroup id='B234AED44A'><strike id='B234AED44A'><sup id='B234AED44A'></sup></strike><code id='B234AED44A'></code></optgroup>
        1. <b id='B234AED44A'><label id='B234AED44A'><select id='B234AED44A'><dt id='B234AED44A'><span id='B234AED44A'></span></dt></select></label></b><u id='B234AED44A'></u>
          <i id='B234AED44A'><strike id='B234AED44A'><tt id='B234AED44A'><pre id='B234AED44A'></pre></tt></strike></i>

          fashion

          fashion

          author:leisure time    Page View:3147
          Fiona Marshall, president of the Novartis research hub in Cambridge, Mass., speaks Thursday during the STAT Future Summit. STAT

          Swiss drugmaker Novartis’ research and development hub has a new name — and a new guiding strategy.

          The hub, which is headquartered in Cambridge, Mass., and for years has been known as Novartis Institutes for BioMedical Research, or NIBR, will soon simply be known as Novartis Biomedical Research.

          advertisement

          But that’s not the only thing that’s changing, Fiona Marshall, the hub’s president, told a virtual audience Thursday during the 2023 STAT Future Summit. The new name reflects a larger shift by the pharma giant to retool its research strategy — from one driven by the pure pursuit of scientific discovery to a tighter focus on projects likely to yield commercially successful drugs.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          Argenx drug significantly slows progression of nerve disorder
          Argenx drug significantly slows progression of nerve disorder

          AdobeBelgiandrugmakerArgenxsaidMondaythatitsantibodytreatmentcalledVyvgartsignificantlydelayedthepro

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          Why some people catch Covid but never get sick

          ThisscanningelectronmicroscopeimageshowsSARS-CoV-2(yellow)isolatedfromapatient.NIAID/NIHIntheearlies